The global peptide therapeutics market size is growing significantly due to the increasing prevalence of cardiovascular diseases and cancer, advances in peptide therapeutics manufacturing technology, and increasing healthcare expenditure. In addition, growing research and development activities along with a rich peptide therapeutics pipeline is expected to support the growth of the peptide therapeutics market. Patent expiration of several peptide drugs in the coming years will create ample opportunities for the global generic peptide therapeutics market to grow at a significant rate in the forecasted period. Peptides are made up of short chains of amino acid monomers. Peptide therapeutics have applications in several indications such as cancer, central nervous system disorders, respiratory disorders, and cardiovascular diseases; this is due to high selectivity, efficacy and safety of peptides.
Peptide therapeutics market can be categorized on the basis of marketing type, route of administration, application, and. Based on marketing type, the peptide therapeutics market can be categorized as generic peptides and branded peptides. On the basis of route of administration, peptide therapeutics market can be segmented as oral mode of administration and parenteral mode of administration.
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=peptide-therapeutics-market
In addition, based on applications, the market can be categorized as gastrointestinal disorders, infection, respiratory disorders, central nervous system, metabolic disorders, cardiovascular diseases, hematological disorders, acromegaly, cancer and others. Cancer leads the market due to increasing number of new cancer cases.
Some of the major players operating in the global peptide therapeutics market are, Sanofi, Teva Pharmaceutical Industries Ltd., Novartis AG, Ipsen S.A., AstraZeneca plc, Amgen Inc., Eli Lilly and Company, Lonza Group Ltd., Merck & Co. Inc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bachem Holding AG, PolyPeptide Group, and CordenPharma International GmbH.
This post was originally published on Financial Sector